Concepedia

Hani Kushlaf

HK

Statistics

Publications

12

Citations

597

H-Index

11

Active since

2018

Affiliations

University of Cincinnati(Current)

University of California, Irvine

Ludwig-Maximilians-Universität München

University of Messina

Erasmus MC

Hani Kushlaf is an author at University of Cincinnati specializing in neurology, pompe disease pharmacotherapy, and pharmacotherapy.

ORCID

Publications per year

2018–2024

12

Publications

12

Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial

Jordi Díaz‐Manera, Priya S. Kishnani, Hani Kushlaf et al. · The Lancet Neurology · 2021 · 184 citations · Full text

, , +3

Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial

Benedikt Schoser, Mark Roberts, Barry J. Byrne et al. · The Lancet Neurology · 2021 · 132 citations · Full text

, , +3

Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks

Priya S. Kishnani, Jordi Díaz‐Manera, António Toscano et al. · JAMA Neurology · 2023 · 55 citations · Full text

, , +8

Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS)

Richard J. Barohn, Byron J. Gajewski, Mamatha Pasnoor et al. · JAMA Neurology · 2020 · 47 citations · Full text

, , +17

Genotype–phenotype correlations in valosin-containing protein disease: a retrospective muticentre study

Marianela Schiava, Chiseko Ikenaga, Rocío N. Villar‐Quiles et al. · Journal of Neurology Neurosurgery & Psychiatry · 2022 · 41 citations · Full text

, , +14

1–5 of 12